跳转至内容
Merck

Y0001459

用于系统适应性的氟羟氢化泼尼松

European Pharmacopoeia (EP) Reference Standard

别名:

醋酸曲安奈德, 9α-氟-11β,16α,17α,21-四羟基-1,4-孕甾二烯-3,20-二酮-16,17-丙酮化合物, 9α-氟-16α-羟基波尼松龙 16α,17α-丙酮化合物

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C24H31FO6
CAS号:
分子量:
434.50
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

triamcinolone

製造商/商標名

EDQM

應用

pharmaceutical (small molecule)

格式

neat

儲存溫度

2-8°C

SMILES 字串

[H][C@@]12CCC3=CC(=O)C=C[C@]3(C)[C@@]1(F)[C@@H](O)C[C@@]4(C)[C@@]2([H])C[C@H]5OC(C)(C)O[C@@]45C(=O)CO

InChI

1S/C24H31FO6/c1-20(2)30-19-10-16-15-6-5-13-9-14(27)7-8-21(13,3)23(15,25)17(28)11-22(16,4)24(19,31-20)18(29)12-26/h7-9,15-17,19,26,28H,5-6,10-12H2,1-4H3/t15-,16-,17-,19+,21-,22-,23-,24+/m0/s1

InChI 密鑰

YNDXUCZADRHECN-JNQJZLCISA-N

基因資訊

human ... NR3C1(2908)

正在寻找类似产品? 访问 产品对比指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Triamcinolone acetonide for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

包裝

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他說明

Sales restrictions may apply.

象形圖

Health hazardExclamation mark

訊號詞

Danger

危險聲明

危險分類

Acute Tox. 4 Oral - Repr. 1B

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


从最新的版本中选择一种:

分析证书(COA)

Lot/Batch Number

抱歉,我们目前尚未线上提供该产品的COA。

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Taygan Yilmaz et al.
Ophthalmology, 116(5), 902-911 (2009-05-05)
To compare intravitreal triamcinolone acetonide (IVTA) injection versus no treatment or sub-Tenon triamcinolone acetonide (STTA) injection in improving visual acuity (VA) of patients with refractory diabetic macular edema (DME; unresponsive to focal laser therapy). Diabetic macular edema is the leading
Daniel I Rhon et al.
Annals of internal medicine, 161(3), 161-169 (2014-08-05)
Corticosteroid injections (CSIs) and physical therapy are used to treat patients with the shoulder impingement syndrome (SIS) but have never been directly compared. To compare the effectiveness of 2 common nonsurgical treatments for SIS. Randomized, single-blind, comparative-effectiveness, parallel-group trial. (ClinicalTrials.gov:
Kent W Small et al.
Ophthalmology, 121(4), 952-958 (2014-02-11)
To report a series of cases with fungal endophthalmitis occurring after intravitreal injection of triamcinolone derived from a single lot prepared by a compounding pharmacy. Retrospective, observational case series. Seventeen eyes treated with triamcinolone obtained from a single lot subsequently
Luis A Solchaga et al.
Journal of orthopaedic research : official publication of the Orthopaedic Research Society, 32(1), 145-150 (2013-09-11)
This study compared the effect of intra-tendon (IT) delivery of recombinant human platelet-derived growth factor-BB (rhPDGF-BB), platelet-rich plasma (PRP) and corticosteroids in a rat tendinopathy model. Seven days after collagenase induction of tendinopathy, a 30-µl IT injection was administered. Treatments
C M Jermak et al.
Survey of ophthalmology, 52(5), 503-522 (2007-08-28)
Triamcinolone acetonide has been effectively used in ocular therapeutics for over 50 years. Its use has increased dramatically in recent years for periocular and intraocular treatment of retinal vasculature disease and uveitis. This comprehensive review discusses the pharmacokinetics of triamcinolone

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门